{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004324","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.093518+00:00","generated_at":"2026-05-31T13:45:17.089451+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026","bullets":["Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.","Workforce reduction of 40% (discontinuing HBV discovery); one-time restructuring charge $3-4M in Q3.","Cash, cash equivalents & investments $148.5M; cash runway extended into Q4 2026 (2024 cash burn guidance $63-67M).","IM-PROVE I data: 33% of patients achieved undetectable HBsAg; 67% for those with baseline HBsAg <1000 IU/mL.","LNP litigation vs Moderna trial set for April 21, 2025; Pfizer/BioNTech ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004324","json":"https://secwatch.observer/filing/0001171843-24-004324.json","markdown":"https://secwatch.observer/filing/0001171843-24-004324.md","text":"https://secwatch.observer/filing/0001171843-24-004324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324004324/0001171843-24-004324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324004324/f8k_080124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:45:17.089451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}